

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget approvato da contratto (€)
http://www.aifa.gov.it/sites/default/files/Siciliano_Gabriele_Bando_2017.pdf	TRS-2018-00001625	Siciliano Gabriele	Department of Clinical and Experimental Medicine, Neurological Clinics, University of Pisa	Deflazacort TREATment in LMNA-related congenital muscular dystrophy: study of clinical effectiveness and search for reliable biomarkers.	373.508,48
http://www.aifa.gov.it/sites/default/files/Cannavo_Salvatore_Bando_2017.pdf	TRS-2018-00001591	Cannavò Salvatore	UNIVERSITY OF MESSINA	IDENTIFICATION AND VALIDATION OF NEW CIRCULATING BIOMARKERS FOR PREDICTION OF GH-SECRETING PITUITARY TUMORS SENSITIVITY TO FIRST GENERATION SOMATOSTATIN ANALOGS TREATMENT AND IMPROVEMENT OF ACROMEGALY MANAGEMENT	474.089,20
http://www.aifa.gov.it/sites/default/files/Scaroni_Carla_Bando_2017.pdf	TRS-2018-00001632	Scaroni Carla	Endocrine Unit, Department of Medicine DIMED, University-Hospital of Padova	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study	377.000,00
http://www.aifa.gov.it/sites/default/files/Crotti_Lia_Bando_2017.pdf	TRS-2018-00001470	Crotti Lia	IRCCS Istituto Auxologico Italiano	Novel therapy for the Long QT Syndrome type 2 based on the mechanism of action of the disease-causing mutations	643.980,26
http://www.aifa.gov.it/sites/default/files/Chiarion_Sileni_Vanna_Bando_2017.pdf	TRS-2018-00001567	Chiarion Sileni Vanna	Istituto Oncologico Veneto	Circulating markers as gender-specific predictors of response to Immune Checkpoint Inhibitors in melanoma and non-small-cell lung cancer patients	Contratto non stipulato in seguito a rinuncia del finanziamento da parte del PI
http://www.aifa.gov.it/sites/default/files/Perno_Carlo_Federico_Bando_2017.pdf	TRS-2018-00001336	Perno Carlo Federico	Università degli studi di Milano	Strategies to Contain HIV Drug-Resistance Emergence in Virologically Suppressed Patients Requiring Antiretroviral Therapy Optimization: Unraveling the Role of Mutational Burden in PBMCs	499.958,54
http://www.aifa.gov.it/sites/default/files/Sacca_Francesco_Bando_2017.pdf	TRS-2018-00001358	Saccà Francesco	UNIVERSITY FEDERICO II	A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethylfumarate in Friedreich Ataxia (DMF-FA-201).	390.000,00

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget approvato da contratto (€)
http://www.aifa.gov.it/sites/default/files/Villa_Erica_Bando_2017.pdf	TRS-2018-00001238	Villa Erica	University of Modena and Reggio Emilia	Gender-related response to Tyrosine Kinase-Inhibitor drugs in hepatocellular carcinoma	1.313.333,00
http://www.aifa.gov.it/sites/default/files/Voso_Maria_Teresa_Bando_2017.pdf	TRS-2018-00001687	Voso Maria Teresa	Fondazione GIMEMA Franco Mandelli Onlus	Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemotherapy, according to the BM-blast proportion (ACROBAT trial)	1.500.000,00
http://www.aifa.gov.it/sites/default/files/Bassi_Claudio_Bando_2017.pdf	TRS-2018-00001695	Bassi Claudio	AOUI Verona	Antibiotic stewardship program in pancreatic surgery: a multicenter time series analysis.	405.936,00
http://www.aifa.gov.it/sites/default/files/Milani_Paolo_Bando_2017.pdf	TRS-2018-00001624	Milani Paolo	Foundation IRCCS Policlinico San Matteo	A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis.	244.265,00
http://www.aifa.gov.it/sites/default/files/Disma_Nicola_Massimo_Bando_2017.pdf	TRS-2018-00001250	Disma Nicola Massimo	Istituto Giannina Gaslini	Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children. The TREX Study.	675.308,00